Lymphocyte Depleting and Modulating Therapies for Chronic Lung Allograft Dysfunction

Area of Science:

• Immunology
• Transplantation Medicine
• Pulmonology

Background:

• Chronic lung allograft dysfunction (CLAD) significantly limits long-term survival post-lung transplantation.
• Current interventions offer only temporary stabilization or modest improvements in lung function.
• Effective treatments to prevent CLAD onset or halt its progression are urgently needed.

Purpose of the Study:

• To review the efficacy of lymphocyte-depleting and immunomodulating therapies for progressive CLAD.
• To evaluate treatments beyond standard maintenance immunosuppression.
• To explore potential future therapeutic strategies.

Main Methods:

• Review of existing literature on lymphocyte-targeting therapies.
• Analysis of modalities including anti-thymocyte globulin, alemtuzumab, methotrexate, cyclophosphamide, total lymphoid irradiation, and extracorporeal photopheresis.
• Assessment of treatment efficacy and side effect profiles.

Main Results:

• Extracorporeal photopheresis, anti-thymocyte globulin, and total lymphoid irradiation appear to be the most viable second-line treatment options for progressive CLAD.
• These therapies offer a balance between efficacy and manageable side effects.
• The interpretation of results is limited by the scarcity of randomized controlled trials.

Conclusions:

• Lymphocyte-targeting therapies represent a critical area for managing progressive CLAD.
• Extracorporeal photopheresis, anti-thymocyte globulin, and total lymphoid irradiation are promising options for advanced CLAD.
• Further high-quality research, particularly randomized controlled trials, is essential to confirm efficacy and optimize treatment strategies.